| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 – |
| 09 Nov 2026 | SCHEDULE 13G |
| 22 Sep 2026 |
Form 4: Gerber Hans-Peter, CHIEF SCIENTIFIC OFFICER
Received 3,750 shares by exercise or conversion · Gave up 1,345 shares to cover exercise price or tax ($20.6K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – |
| 30 Jul 2026 | SCHEDULE 13G |
| 09 Jun 2026 |
Form 4: Petree Daniel H, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Panek James P, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Dybbs Michael, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Matsui Connie, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Wigginton Jon Marc, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Lobacki Joseph M, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Jagpal Sukhi, Director
Granted 10,000 Stock Option (right to buy) |
| 09 Jun 2026 |
Form 4: Hunter Heidi, Director
Granted 10,000 Stock Option (right to buy) |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), and the following proposals were adopted: |
| 02 Jun 2026 |
Form 4: Chow Gregory K., CFO
Received 2,500 shares by exercise or conversion |
| 15 May 2026 | SCHEDULE 13G |
Loading...